EMD Serono Research & Development Institute, Inc. $MRK.DE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS8
PHASE 3 / 2-35
RECRUITING4
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tepotinib NCT02864992 |
P2 | Active, not recruiting | Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification; Lung Adenocarcinoma Stage IIIB/IV | 337 | 2022-05-16 (+50 mo) |
| Avelumab NCT05327530 |
P2 | Active, not recruiting | Locally Advanced or Metastatic Urothelial Carcinoma | 256 | 2025-06-20 (-14 mo) |
| Avelumab NCT03815643 |
P3 | Active, not recruiting | Solid Tumors | 205 | 2026-11-24 (+34 mo) |
| M9140 NCT06710132 |
P1/2 | Active, not recruiting | Solid Tumors; Gastric Cancer | 184 | 2027-12-23 (-13 mo) |
| ELOWEN-1 NCT07332481 |
P3 | Recruiting | Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE) | 202 | 2029-05-24 |
| Enpatoran NCT07355218 |
P3 | Recruiting | Systematic Lupus Erythematosus; Cutaneous Lupus Erythematosus | 202 | 2029-05-25 |
| Precemtabart tocentecan NCT07549412 |
P3 | Recruiting | Metastatic Colorectal Cancer | 1020 | 2029-10-16 |
| Enpatoran NCT07840287 |
P3 | Recruiting | Systemic Lupus Erythematosus (SLE); Cutaneous Lupus Erythematosus (CLE) | 404 | 2031-09-01 |